Breakthrough cancer pain usually rears its ugly head after it limits the patient’s physical activity. Approaches for breakthrough cancer pain are frequently discussed and researched at pain practices around the world.
A report in PainMedicineNews.com reflects on a recent study by Dr. Yvonne D’Arcy that looks at several approaches for breakthrough cancer pain. These approaches include:
“Lifestyle changes such as use of assistive devices or exercises that limit joint movement; palliative chemotherapy, radiation therapy or surgery; Non pharmacologic therapies for adjunct pain relief, such as relaxation or distraction and the use of medications such as ATC opioid therapy or rapid onset opioids.”
This topic is a hot-button issue around the Globe. Dr. Franco de Conno, the Honorary Director of the European Association for Palliative Care had this to say about Cancer Pain Treatment:
“The life of the patient, cancer patient in pain, is a terrible life and I think the healthcare professional, they not only they can improve, they have to improve the life of the patient controlling pain by adequate treatment. The adequate treatment for strong pain is strong opioid.“
The Sacramento Bee recently reported that the European Union acquired the drug BREAKYL, known as ONSOLIS in the U.S.
BREAKYL and ONSOLIS are used for the management of breakthrough pain patients who are tolerant to opioid therapy for their underlying persistent cancer pain.